As pharmaceutical manufacturers push toward lower detection limits, tighter impurity thresholds, and faster development cycles, elemental analysis has become a more critical part of quality and compliance.

Regulatory frameworks such as U.S. Pharmacopeia (USP) <232>, USP <233>, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3D have formalized and intensified industry focus on elemental impurity testing, particularly for trace-level metals that might present patient safety risks even at very low concentrations.

USP <232> establishes limits for elemental impurities in pharmaceutical products, while USP <233> describes analytical procedures used to evaluate them. ICH Q3D adds a risk-based framework for controlling elemental impurities throughout the product life cycle. Together, these standards have pushed pharmaceutical laboratories toward increasingly sensitive analytical workflows, particularly ICP-MS and ICP-OES systems capable of trace-level detection.

However, although much of the industry’s attention naturally falls on instrument sensitivity, many of the factors that determine whether results are reliable occur earlier in the workflow. Sample preparation, digestion, calibration alignment, traceability, and method validation all influence whether elemental impurity data can withstand regulatory scrutiny.

These workflows rely heavily on certified reference materials (CRMs) and calibration standards used to establish traceable instrument response and verify analytical accuracy.

“Today, expectations for low detection-level impurities are regulatory requirements because of increased health risks due to impurities,” says Suresh Ramachandran, an analytical chemist with more than 20 years of experience in pharmaceutical elemental analysis. “Traceability of documentation related to NIST standards and data validated against them is extremely important.”

That pressure is especially visible in newer and more complex formulations where low concentrations and challenging matrices can make sample preparation, calibration, and method validation more difficult.

Why sample preparation matters

In elemental impurity testing, even advanced instrumentation can’t fully compensate for inconsistent sample preparation or poorly controlled digestion workflows.

Before analysis can occur, pharmaceutical samples often undergo acid digestion to break down complex organic materials into solutions suitable for inductively coupled plasma mass spectrometry (ICP-MS) or inductively coupled plasma–optical emission spectroscopy (ICP-OES) analysis. Closed-vessel microwave digestion is widely used in these workflows because it provides controlled digestion conditions and can help reduce contamination or analyte loss when properly validated.

Pharmaceutical matrices vary significantly. Tablets, injectables, biologics, oils, gels, and peptide formulations can all behave differently during digestion and analysis. Incomplete digestion, contamination, analyte loss, or instability introduced during preparation can directly affect recovery and accuracy downstream.

In many cases, digestion itself becomes part of the validated analytical method.

A poorly controlled digestion workflow can create matrix-related effects that alter recovery, suppress signal, or affect instrument response before the sample ever reaches the detector. Even small inconsistencies can become problematic when laboratories are working near reporting thresholds measured in parts per billion.

“The instrument only sees what the preparation process gives it,” says Brian Alexander, chief technical officer of Inorganic Ventures. “If digestion, matrix behavior, or calibration alignment is not controlled, the final number may look precise but still be difficult to defend.”

Laboratories often rely on internal standards, spike recovery studies, blanks, and system suitability checks to verify that matrix effects, contamination, or instrument drift aren’t compromising results. When those checks fail, the consequences can include investigations, repeat testing, delayed batch release, or added scrutiny during audit review.

At the same time, laboratories are under pressure to increase throughput while maintaining defensible results.

“Less turnaround time is important because firms want to hit the market as quickly as possible,” Ramachandran says. “In CDMO environments, where companies develop and manufacture drugs for other pharmaceutical firms, speed can also help attract and retain clients.”

That combination of lower detection limits, complex matrices, and compressed timelines increases the importance of repeatable workflows long before the instrument generates a result.

Validation changes the equation

In pharmaceutical environments, analytical methods aren’t simply created and used. They’re validated, documented, and expected to remain consistent throughout the product life cycle. That means the standards and reagents selected during development can become part of the method’s long-term foundation.

“During development, we need trusted analytical standards because throughout the life cycle we have to use the same quality of standards and reagents to get a rugged method,” Ramachandran says.

In pharmaceutical validation language, a rugged or robust method is one that continues to produce reliable results across analysts, instruments, laboratories, reagent lots, and routine operating conditions. That reliability becomes increasingly important as impurity thresholds tighten and regulatory scrutiny increases.

In practice, calibration standards, digestion conditions, preparation procedures, internal controls, and documentation all become part of the validated analytical framework supporting the method.

Once validated, changes can become difficult. Laboratories might need additional verification, documentation, or partial revalidation if standards, reagents, digestion conditions, or calibration workflows change significantly. In that environment, a standard isn’t simply a purchased material; it becomes part of the validated method’s evidence package.

That’s why traceability and documentation are central to pharmaceutical elemental analysis. During regulatory filings and inspections, laboratories may need to demonstrate traceability to recognized standards, provide certificates of analysis, document uncertainty or preparation details, and show that methods remain stable and repeatable over time.

“As an end user, our manufacturing firms have to provide traceability and certificates during filings,” Ramachandran says. “If the standard cannot be traced and supported, the result becomes harder to defend during validation or audit.”

Where standards become critical

As elemental impurity testing becomes more demanding, calibration standards increasingly influence method reliability.

Matrix-related effects, contamination, drift, and poor standard selection can all affect analytical performance, particularly when laboratories are analyzing multiple sample types in the same systems.

“Analytical standards may be qualified using advanced analytical instruments, but end users may have older instruments analyzing multiple matrices that can become contaminated,” Ramachandran says. “At that point, traceability certificates and supporting spectra or analytical records help us evaluate method performance.”

Because validated methods depend on consistency over time, laboratories increasingly prioritize standards that can support regulated workflows in development, validation, and routine testing.

“As regulatory expectations tighten and detection limits get lower, the margin for analytical error narrows,” says Inorganic Ventures’ Alexander. “In pharmaceutical testing, you are often working at trace levels where calibration, matrix behavior, and method consistency all matter. Small biases can compound very quickly when laboratories are working near reporting thresholds or specification limits.”

For pharmaceutical labs, supplier selection is increasingly tied to whether standards can support validated methods over time. Traceability, purity, stability, documentation, technical support, and reliable availability all influence whether those standards can support defensible results.

As pharmaceutical products become more complex and regulatory scrutiny around elemental impurities continues to increase, laboratories face growing pressure to produce results that are not only accurate but also defensible.

In that environment, elemental analysis no longer begins at the instrument. It begins with the integrity of the workflow behind it.